IRIS
AMATA, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.414
EU - Europa 4.405
AS - Asia 3.592
AF - Africa 618
SA - Sud America 507
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.554
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.201
SG - Singapore 1.588
IT - Italia 1.437
RU - Federazione Russa 1.311
CN - Cina 932
BR - Brasile 430
DE - Germania 406
CI - Costa d'Avorio 375
IE - Irlanda 354
VN - Vietnam 290
HK - Hong Kong 248
KR - Corea 198
FR - Francia 194
FI - Finlandia 173
CA - Canada 147
GB - Regno Unito 118
UA - Ucraina 104
SN - Senegal 83
ES - Italia 67
NG - Nigeria 64
IN - India 63
BD - Bangladesh 59
JP - Giappone 59
NL - Olanda 44
PL - Polonia 44
MX - Messico 35
AR - Argentina 31
SE - Svezia 29
CZ - Repubblica Ceca 28
ZA - Sudafrica 28
ID - Indonesia 27
UZ - Uzbekistan 20
TR - Turchia 18
AT - Austria 17
IQ - Iraq 17
KE - Kenya 16
BE - Belgio 14
EC - Ecuador 14
MA - Marocco 13
AU - Australia 12
BJ - Benin 12
CH - Svizzera 12
GR - Grecia 12
CL - Cile 10
LT - Lituania 9
SA - Arabia Saudita 9
CO - Colombia 8
DZ - Algeria 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
JM - Giamaica 7
EG - Egitto 6
HU - Ungheria 5
IL - Israele 5
IR - Iran 5
JO - Giordania 5
PE - Perù 5
AL - Albania 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
HN - Honduras 4
KZ - Kazakistan 4
LB - Libano 4
MY - Malesia 4
RS - Serbia 4
AZ - Azerbaigian 3
ET - Etiopia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
OM - Oman 3
PH - Filippine 3
PY - Paraguay 3
RO - Romania 3
TH - Thailandia 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
BY - Bielorussia 2
CM - Camerun 2
GT - Guatemala 2
HR - Croazia 2
NO - Norvegia 2
PA - Panama 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CG - Congo 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 15.544
Salva come PNG Salva come JPEG
Città #
Dallas 1.351
Singapore 957
Santa Clara 673
Moscow 620
Chandler 617
San Jose 470
Ashburn 445
Catania 389
Abidjan 375
Dublin 352
Chicago 332
Munich 300
Hefei 234
Seoul 196
Beijing 159
Boardman 144
Los Angeles 133
Civitanova Marche 130
Helsinki 125
Lauterbourg 110
Jacksonville 105
Nanjing 96
Ho Chi Minh City 93
Andover 89
Lawrence 89
Cambridge 88
Dakar 83
Houston 78
Toronto 67
Hanoi 64
New York 64
Tokyo 56
Council Bluffs 54
Rome 53
Naples 51
Bremen 48
Des Moines 47
Montreal 46
São Paulo 45
Buffalo 44
Columbus 37
Hong Kong 37
The Dalles 36
Lagos 35
Warsaw 32
Brooklyn 31
Milan 31
Denver 29
Wilmington 28
Saint Petersburg 27
Palermo 26
Amsterdam 24
Nanchang 24
Orem 24
Atlanta 23
Hebei 22
Poplar 22
Phoenix 21
London 20
Abuja 19
Johannesburg 19
Messina 19
Rio de Janeiro 19
Dong Ket 18
Jakarta 18
Jiaxing 18
Sala Baganza 18
Brno 17
Jyväskylä 17
Madrid 17
Ottawa 17
Shenyang 17
Changsha 16
Da Nang 16
Belo Horizonte 15
Florence 15
Haiphong 15
Stockholm 15
Lappeenranta 14
Paris 14
Seattle 14
Centro 13
Chennai 13
Cuneo 13
Grafing 13
Marseille 13
Washington 13
Boydton 12
Cagliari 12
Cotonou 12
Leawood 12
San Giovanni la Punta 12
Tashkent 12
Bari 11
Brussels 11
Curitiba 11
Mumbai 11
Tianjin 11
Frankfurt am Main 10
Guangzhou 10
Totale 10.593
Salva come PNG Salva come JPEG
Nome #
C-5'-Triazolyl-2'-oxa-3'-aza-4'a-carbanucleosides: Synthesis and biological evaluation 505
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 437
Comprehensive data on a 2D-QSAR model for Heme Oxygenase isoform 1 inhibitors 297
Composti inorganici [Cap. 6] 275
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 207
Involvement of sigma 2 receptor on motor disorder 207
Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer 199
4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes 198
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 195
[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT7 receptor 189
Combination of heme oxygenase-1 inhibition and sigma receptor modulation for anticancer activity 186
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 185
DNA intercalators based on (1,10-phenanthrolin-2-yl)isoxazolidin-5-yl core with better growth inhibition and selectivity than cisplatin upon head and neck squamous cells carcinoma 180
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 179
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 176
Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells 175
Antioxidant activity of (+)-Pentazocine on activated microglia 174
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 171
A pseudouridine isoxazolidinyl nucleoside analogue structural analysis: A morphological approach 169
(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties 165
A structure-and ligand-based virtual screening of a database of “small” marine natural products for the identification of “blue” sigma-2 receptor ligands 161
Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors 158
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 157
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review 156
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 154
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 152
Development of Sigma Receptors Nitric Oxide Photodonor Ligands with Antiproliferative Activity 151
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 149
Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma 149
Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform 1 Inhibitors 149
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 145
Synthesis of “no-light activated” Ciprofloxacin and Norfloxacin derivatives as potential biofilm dispersant agents 142
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 141
Design of Small Molecules for Oncological and Neurodegenerative Diseases 140
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 140
Cytotoxicity Profiles and Neuroprotective Properties of the Novel Ifenprodil Analogues as Sigma Ligands 137
Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors 137
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 136
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 132
La modellistica molecolare applicata ai recettori Sigma-1 e Sigma-2: un excursus 132
CNS permeability parameters determination through a statistical analysis driven approach 132
New selective Sigma-1/HDACi prodrugs for neurodegenerative disorders 131
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 129
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 129
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 129
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 128
Development of NO-releasing sigma receptor hybrids as anticancer agents 128
Development of novel H2S-donor sigma receptor hybrids for the management of pain. 127
Tumor Targeting Sigma Receptor Ligands: Development of New Molecular Hybrids as Anticancer Therapeutics 126
Fourfold filtered statistical/computational approach for the identification of imidazole compounds as HO-1 inhibitors from natural products 125
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 124
Sigma-2 receptor ligands QSAR model dataset 124
Novel structural insight into inhibitors of heme oxygenase-1 (ho-1) by new imidazole-based compounds: Biochemical and in vitro anticancer activity evaluation 124
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 124
Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase 123
Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth 121
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 120
Morphing of ibogaine: A successful attempt into the search for sigma-2 receptor ligands 118
Novel Sigma Receptors Ligands-Nitric Oxide Photodonor: Molecular Hybrids for Double-Targeted Antiproliferative Effect 117
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 116
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity 116
Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies 116
Exploring Structural Requirements for Sigma-1 Receptor Linear Ligands: Experimental and Computational Approaches 115
Haloperidol Metabolite II Valproate Ester: Antiangiogenic Activity in Human Microvascular Retinal Endothelial Cells 115
Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents 115
Structure-activity relationships of mixed σ1R/σ2R ligands with antiproliferative and anticancer effects 114
S2RSLDB: A comprehensive manually curated, internet-accessible database of the sigma-2 receptor selective ligands 112
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 111
Synthesis of Novel Benzylpiperazine Derivatives as Ligands for the σ1 Receptor 111
Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands 110
NLC as promising platform to deliver new prodrugs in the treatment of ophthalmic cancer 109
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 109
Tuning Properties for Blood-Brain Barrier Permeation: A Statistics-Based Analysis 109
In-vitro evaluation of a new benzomorphan-based ligand 108
DESIGN, SYNTHESIS, MOLECULAR MODELING AND PHARMACOLOGICAL EVALUATION OF NOVEL DIAZABICYCLO[4.3.0]NONANE AND 2,7-DIAZASPIRO[3.5]NONANE AS SIGMA RECEPTORS LIGANDS 107
Interaction of new sigma ligands with biomembrane models evaluated by differential scanning calorimetry and Langmuir-Blodgett studies 107
Discovery of 3-(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligands 106
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 104
Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation 104
Evaluation of N-substitution in 6,7-benzomorphan compounds 102
Investigation of Tau-Dependent Epigenetic Reprogramming in Alzheimer’s Disease 101
Heme Oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia 101
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 101
Nanostructured lipid carrier for the ophthalmic delivery of haloperidol metabolite II valproate ester (±)-MRJF22: A potential strategy in the treatment of uveal melanoma 100
Pain management: new long-acting opioid ligands 100
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 98
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 97
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics for Pain Treatment 95
Design, Synthesis, and Evaluation of Novel (−)‐cis‐N‐Normetazocine Derivatives: In Vitro and Molecular Modeling Insights 95
NOVEL N-NORMETAZOCINE DERIVATIVES WITH SIGMA-1 RECEPTOR ANTAGONIST PROFILE AS POTENTIAL ANALGESICS FOR INFLAMMATORY PAIN MANAGEMENT 95
Identification of Potentially Potent Heme Oxygenase 1 Inhibitors through 3D-QSAR Coupled to Scaffold-Hopping Analysis 95
SYNTHESIS, COMPUTATIONAL INSIGHTS, AND EVALUATION OF NOVEL SIGMA RECEPTORS LIGANDS 91
Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors 89
Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors 88
Discovery and computational studies of piperidine/piperazine-based compounds endowed with sigma receptor affinity 88
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 87
Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents 86
HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic 85
MOR/DOR Dual-Target Approach: 2S-LP2 Effects in Inflammatory and Neuropathic Pain 85
Development of selective sigma-1 receptor ligands with antiallodynic activity: A focus on piperidine and piperazine scaffolds 83
Totale 13.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.498
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 0 0 0 0 0 0 30
2021/2022718 61 100 31 17 115 5 105 31 42 20 10 181
2022/20231.918 138 124 30 241 116 248 10 501 348 34 91 37
2023/20241.101 56 150 57 60 75 310 66 44 6 21 177 79
2024/20253.577 120 493 145 264 586 424 333 179 322 240 227 244
2025/20267.347 452 425 1.528 503 1.001 1.466 622 160 431 416 238 105
Totale 15.997